Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MannKind Corporation

http://www.mannkindcorp.com

Latest From MannKind Corporation

Oramed Failure Highlights Insurmountable Challenge Of Oral Insulin Delivery

Oramed's attempts to advance an oral formulation of insulin for type 2 diabetes patients have been scuppered with a Phase III fail that has sunk the stock.

Metabolic Disorders Clinical Trials

Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023

After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.

Strategy Companies

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

Sales & Earnings Strategy

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

Commercial Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Other Names / Subsidiaries
    • QrumPharma, Inc.
UsernamePublicRestriction

Register